Mereo BioPharma Group plc MREO

Rank #2332 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

24.2

P/E

-5.3

P/B

4.57

ROE

-85.6%

Op. Margin

–%

Debt Ratio

31%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -5.3x, P/B 4.57x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -85.6%. Ranks in the top 93% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 31%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Poor

Revenue decline of 100.0% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2023	$0.0B	$-0.1B	$-0.0B	$0.1B	–	28
2024	$0.0B	$-0.0B	$-0.0B	$0.1B	-284.2	31
2025	$0.0B	$-0.0B	$-0.0B	$0.1B	–	31

← See the full screener